(Q41476034)

1 October 2017

1 reference

title

Treatment in germ cell tumours: state of the art. (English)

1 reference

1 October 2017

Tjan-Heijnen VC

1

1 reference

1 October 2017

Oosterhof GO

series ordinal

2

1 reference

1 October 2017

de Wit R

series ordinal

3

1 reference

1 October 2017

De Mulder PH

series ordinal

4

1 reference

1 October 2017

publication date

1 April 1997

1 reference

European Journal of Surgical Oncology

1 October 2017

published in

1 reference

1 October 2017

volume

23

1 reference

1 October 2017

issue

2

1 reference

1 October 2017

page(s)

110-117

1 reference

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

VP16-213 as a single agent in advanced testicular tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Current optimum management of anaplastic germ cell tumours of the testis and other sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Accelerated chemotherapy for poor prognosis germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Chemotherapy of disseminated testicular cancer a random prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC).

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Post-orchiectomy management in stage I testicular seminoma: elective irradiation or surveillance?

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Ifosfamide in refractory male germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0748-7983%2897%2980002-9

7 January 2021

10.1016/S0748-7983(97)80002-9

Identifiers

DOI

1 reference

1 October 2017

1 reference